ReviewTheranostics2019
Protein Delivery into the Cell Cytosol using Non-Viral Nanocarriers.
Review in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 106 citations in OpenAlex.
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Engineering the Future: Strategic Advances in Extracellular Vesicle-Mediated Drug Delivery Systems.International journal of nanomedicine · 2026Review
- Synergistic Effects of Polycationic and Polyfluorinated Functionalities for Efficient Intracellular Protein Delivery.Biomacromolecules · 2025Article
- Nanoparticles to target asthma.American journal of physiology. Lung cellular and molecular physiology · 2024Review
- A small-molecule carrier for the intracellular delivery of a membrane-impermeable protein with retained bioactivity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The Pvc15 ATPase selectively associates effector proteins with theRoyal Society open science · 2024Article
- Polymers of functionalized diaminopropionic acid are efficient mediators of active exogenous enzyme delivery into cells.Scientific reports · 2024Article
- Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?World journal of hepatology · 2024Article
- Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy.Journal of translational medicine · 2023Review
- Cellular Internalization and Exiting Behavior of Zwitterionic 4-Armed Star-Shaped Polymers.Molecules (Basel, Switzerland) · 2023Article
- Protective Effects of a Jellyfish-Derived Thioredoxin Fused with Cell-Penetrating Peptide TAT-PTD on HInternational journal of molecular sciences · 2023Article
- Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells.Pharmaceutics · 2023Review
- A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis.Nature communications · 2023Article
- Direct Cytosolic Delivery of Citraconylated Proteins.Pharmaceutics · 2023Article
- Intracellular delivery of therapeutic proteins. New advancements and future directions.Frontiers in bioengineering and biotechnology · 2023Review
- The improving strategies and applications of nanotechnology-based drugs in hepatocellular carcinoma treatment.Frontiers in bioengineering and biotechnology · 2023Review
- Comparison of Acoustofluidic and Static Systems for Ultrasound-Mediated Molecular Delivery to T Lymphocytes.Ultrasound in medicine & biology · 2023Article
- Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy.Bioactive materials · 2022Article
- Protein delivery to living cells by thermal stimulation for biophysical investigation.Scientific reports · 2022Article
- In vivo peptide-based delivery of a gene-modifying enzyme into cells of the central nervous system.Science advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
Protein delivery into cells is a potentially transformative tool for treating "undruggable" targets in diseases associated with protein deficiencies or mutations. The vast majority of these targets are accessed via the cytosol, a challenging prospect for proteins with therapeutic and diagnostic relevance. In this review we will present promising non-viral approaches for intracellular and ultimately cytosolic delivery of proteins using nanocarriers. We will also discuss the mechanistic properties that govern the efficacy of nanocarrier-mediated protein delivery, applications of nanomaterials, and key challenges and opportunities in the use of nanocarriers for intracellular protein delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.